A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
ALT-801-241 RESTORE Study: Efficacy and safety of pemvidutide in the treatment of alcohol-associated liver disease (ALD)
Sponsor: Altimmune, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAV9156
U.S. Govt. ID: NCT07009860
Contact: Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the study drug, pemvidutide, as a possible treatment for alcohol associated liver disease or ALD. ALD is a condition in which excessive alcohol use (commonly defined as more than 2 drinks per day for women and 3 drinks per day for men) leads to liver inflammation and damage. Pemvidutide is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration.
Investigator
Gene Im, MD, FAASLD
Do You Qualify?
Are you 18 to 75 years old? Yes No
Have you had significant alcohol use in the past 3 years? (2 or more drinks per day for women; 3 or more drinks per day for men) Yes No
Do you have a body mass index or BMI of at least 25 kg/m2? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE